Equities

Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.83
  • Today's Change-0.215 / -10.54%
  • Shares traded11.13m
  • 1 Year change-80.65%
  • Beta2.0289
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

  • Revenue in USD (TTM)188.87m
  • Net income in USD-400.38m
  • Incorporated2000
  • Employees796.00
  • Location
    Pacific Biosciences of California Inc1305 O'brien DriveMENLO PARK 94025United StatesUSA
  • Phone+1 (650) 521-8000
  • Fax+1 (302) 636-5454
  • Websitehttps://www.pacb.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nano-X Imaging Ltd10.13m-57.47m356.25m164.00--2.03--35.17-0.9974-0.99740.17552.990.0482--6.8961,756.10-27.33-30.98-29.96-35.10-81.80---567.41-1,527.245.09--0.0181--15.47--46.33--114.35--
Anika Therapeutics Inc166.88m-74.18m377.32m357.00--1.80--2.26-5.06-5.0611.3514.170.56421.344.73467,451.00-25.08-5.41-27.37-5.8762.1660.70-44.45-12.603.96--0.00--6.679.56-456.34--3.11--
Butterfly Network Inc71.08m-108.96m380.51m225.00--1.96--5.35-0.5236-0.52360.34070.91440.22290.63824.19315,911.10-34.17---39.55--27.73---153.29--3.20--0.00---10.21--20.76------
MaxCyte Inc45.44m-35.43m431.20m143.00--1.94--9.49-0.3408-0.34080.4372.110.17390.47417.46317,762.90-13.56-13.18-14.25-14.3388.4388.79-77.97-62.9613.40--0.00---6.7219.89-60.89--39.13--
Varex Imaging Corp832.70m34.20m441.31m2.30k23.590.75866.490.5300.45740.457416.4614.220.67581.955.28346,958.302.820.99133.331.1832.1631.704.171.361.892.000.4271--3.962.9359.0818.880.2924--
ZimVie Inc453.38m-54.86m456.31m2.60k--1.16--1.01-2.04-13.2716.8414.290.38581.123.80174,378.50-4.67---5.43--63.1165.51-12.10-8.731.43-0.38840.3737---1.26-16.08-19.50---23.70--
Pacific Biosciences of California Inc188.87m-400.38m497.37m796.00--1.01--2.63-1.50-1.500.70991.810.11252.056.69237,275.10-23.85-16.19-26.63-17.8126.0137.35-211.99-136.217.14-22.460.6444--56.2920.592.39--36.68--
Surmodics Inc120.82m-1.40m555.73m376.00--4.7475.994.60-0.0955-0.09558.558.280.65972.095.64321,332.40-0.7638-1.85-0.8909-2.1874.0282.93-1.16-2.983.22-4.460.1999--32.6510.2794.37---27.02--
Quanterix Corp129.33m-39.71m558.03m441.00--1.66--4.31-1.04-1.043.408.770.30782.374.60293,265.30-9.45-15.96-10.30-17.6657.4252.79-30.71-53.798.99--0.00--15.9626.6066.56--20.07--
Paragon 28 Inc235.44m-59.07m573.67m430.00--3.91--2.44-0.7132-0.71322.841.760.77030.60496.63547,539.60-19.33---23.48--76.67---25.09--1.70-5.300.4295--19.30--28.94------
Iradimed Corp69.48m18.64m607.90m148.0032.807.6331.238.751.461.465.456.290.81091.556.03469,485.3021.7613.1623.8514.5877.2176.5526.8321.468.25144.050.0068.1323.0016.5934.0222.2297.77--
Orthofix Medical Inc771.65m-120.49m608.35m1.63k--1.13--0.7884-3.21-3.2120.5514.350.86541.176.49472,245.40-13.51-8.88-16.22-10.9667.1872.37-15.62-9.281.13-4.940.2005--62.0610.51-666.60--30.01--
AxoGen Inc173.48m-16.54m617.12m426.00--6.45--3.56-0.3829-0.38294.012.180.91171.627.43407,237.10-8.69-13.92-9.93-15.8476.9879.74-9.53-20.282.32-2.940.3297--14.7413.6324.98--17.70--
Simulations Plus Inc66.98m9.65m624.84m192.0065.883.4544.199.330.4740.4743.299.040.3603--5.57348,843.805.197.205.497.6172.5377.6114.4021.29----0.0045.7010.5214.96-20.206.0212.910.8548
Jin Medical International Ltd20.13m2.91m638.71m245.00218.8824.34209.5731.740.01860.01860.12920.16760.55762.384.2282,143.597.8012.8111.2720.9234.7333.5813.9914.602.27--0.27020.003.29-1.076.34-4.80-9.50--
SI-Bone Inc150.71m-40.85m641.67m344.00--3.88--4.26-1.00-1.003.703.970.65861.546.67438,107.60-17.85-27.88-19.57-30.9477.6985.03-27.10-51.098.12--0.18--30.5220.1929.25--52.62--
Data as of Sep 20 2024. Currency figures normalised to Pacific Biosciences of California Inc's reporting currency: US Dollar USD

Institutional shareholders

55.25%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 30 Jun 202433.21m12.20%
The Vanguard Group, Inc.as of 31 Mar 202426.03m9.56%
BlackRock Fund Advisorsas of 31 Mar 202419.33m7.10%
Madrone Advisors LLCas of 31 Mar 202417.59m6.46%
Nikko Asset Management Americas, Inc.as of 30 Jun 202412.64m4.64%
Edmond de Rothschild Asset Management (France) SAas of 31 Mar 202410.51m3.86%
Newton Investment Management North America LLCas of 30 Jun 20248.58m3.15%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20248.40m3.08%
Jackson Square Partners LLCas of 31 Mar 20247.18m2.64%
Deep Track Capital LPas of 31 Mar 20247.00m2.57%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.